glp-1 pancreatic cancer Oncology Reports Ozempic and Pancreatitis: Can Semaglutide
Description
Patients receiving GC therapy represent a highly heterogeneous group, including individuals with SID, short-term hyperglycemia in previously normoglycemic patients initiating GC therapy, SIH in patients with T2DM and PTDM
Medical information, product, reviews, warnings and legal disclaimer Product Legal Disclaimer
The SELECT trial demonstrated a 20% reduction in major cardiovascular events
Potential upside: Improved hepatic and muscle insulin signalling
Barforoush F et al
Semaglutide is a medication belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist family of meds
